Sensus Healthcare earnings date
Want to see SRTS full AI Analyst Report?
Sensus Healthcare (SRTS) Q3 2026 Earnings Report
SRTS Q3 2026 EPS Results
- Actual EPS
- -$0.09
- Consensus EPS
- -$0.06
- Beat/Miss
- Missed by -$0.03
- One Year Ago EPS
- -$0.06
SRTS Q3 2026 Revenue Results
- Actual Revenue
- $6.00M
- Expected Revenue
- $6.61M
- Beat/Miss
- Missed by -$619.00K
- YoY Revenue Growth
- -12.91%
Earnings Announcement Details
- Quarter
- Q3 2026
- Date
- 11/12/2026
- Time
- After Close
- Conference Call
- Thursday, November 12, 2026
Sensus Healthcare's next earnings date is estimated for February 11, 2027, based on past reporting schedules.
Q3 2026 Earnings Call Audio
Q3 2026 Earnings Slide Deck
No slide deck is available for this earnings event.
Q3 2026 Earnings Call Summary
The call was broadly constructive and focused on commercial progress, including the placement of the 1,000th system, higher shipments, stronger gross margin, improved adjusted EBITDA, broader customer engagement, recurring revenue initiatives, and international opportunities. These positives were partially offset by a 13% revenue decline, a larger reported net loss, lower cash, delayed shipments from financing issues, and the need to convert the expanding pipeline into revenue.
Management said its 5 priorities remain unchanged and that it expects to build on this momentum in the fourth quarter, while it “fully expect[s] that 26% to take effect on January 1 in the hospital environment” and confirmed this should occur on 1/1/'27; it also intends to be disciplined as it pursues international expansion, will attend conferences in Europe and Korea during the fourth quarter, aims to place SRT systems in every facility across groups with “about 450-or-more practices nationwide,” and said Sensus Link is seeing customers “all signing up for it.”
- 1,000th SRT System PlacedSensus recently placed its 1,000th SRT system, marking a milestone in building its installed base and physician customer relationships.
- Stronger Pipeline and Broader Customer ReachThe company reported a stronger pipeline, more inbound interest, and engagement across independent dermatology practices and larger physician groups. During the quarter, Sensus secured initial system purchases from two large private equity-backed dermatology groups.
- Expanded Commercial FlexibilityCustomers can purchase systems outright, use financing, enter rental arrangements, or participate in the Fair Deal Agreement program. Of the two private equity-backed groups signed during the quarter, one chose an outright purchase and the other chose the Fair Deal Agreement.
- Large Practice-Group FootprintThe two newly signed private equity-backed groups collectively have approximately 450 or more practices nationwide, with Sensus stating that its goal is to place systems across their facilities.
- Higher System ShipmentsSensus shipped 26 systems in the third quarter of 2026 compared with 16 in the third quarter of 2025. Excluding eight systems delayed from the second quarter by third-party financing delays, the company shipped 18 systems in the quarter.
- Improved Gross Profit and Gross MarginGross profit increased to $3.3 million from $2.7 million, while gross margin improved to approximately 55% from 39% a year ago. The improvement was primarily driven by the mix of systems shipped, including a greater proportion of higher-margin SRT-100 units.
- Lower Cost of Sales and Improved Adjusted EBITDACost of sales decreased to $2.7 million from $4.2 million. Adjusted EBITDA improved to negative $1.5 million from negative $2.4 million in the prior-year quarter.
- SRT-100 Adoption and Margin OpportunityManagement said reimbursement is pushing more U.S. customers toward the lower-priced SRT-100 rather than the SRT-100 Vision. The SRT-100 has higher margins, while the Vision product costs more to manufacture.
- Recurring Revenue InitiativesSensus is continuing to increase utilization within its Fair Deal Agreement program and develop Sensus Link and other software and service opportunities. The company aims to complement equipment sales with recurring revenue tied to system utilization, software, and services.
- Sensus Link AdoptionManagement said Sensus Link is growing on a monthly basis and that customers are signing up. The technology pairs patient data with the SRT-100 system and provides access to remote radiation oncologists or medical physicists when needed.
- Patient Education Website LaunchedTreatSkincancer.com launched in September to help patients understand skin cancer treatment options, including noninvasive approaches. Early engagement included nearly 1,000 visits during the initial launch period and more than 2,000 social media views.
- International Expansion OpportunitiesSensus is pursuing opportunities across Asia Pacific, including Australia, New Zealand, China, and Hong Kong, and plans to attend conferences in Europe and Korea during the fourth quarter. Management said physician interest continues across these markets, with especially encouraging response in Australia.
- Australia Market Access and DemandSRT is already cleared for use in Australia. Management cited a substantial potential need, stating that 30% of Australia's 26 million people will get skin cancer, while the country has approximately 600 dermatologists and about 60 Mohs surgeons. Groups the company is working with reportedly treat approximately 1,000 skin cancer patients per month.
- Potential 26% Hospital-Based Reimbursement IncreaseManagement said CMS has proposed a 26% increase in hospital-based SRT delivery codes for Level 1 radiation treatment delivery and that it fully expects the increase to take effect on January 1, 2027.
- No Revolving Credit BorrowingsSensus ended September with no outstanding borrowings under its revolving line of credit.
- Reduced Research and Development ExpenseResearch and development expense decreased to $1.1 million from $1.8 million, primarily reflecting reduced lobbying costs and lower headcount.
SRTS Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 11, 2027 | 2026 (Q4) | -0.06- | -0.19 | ― | ― |
| Nov 12, 2026 | 2026 (Q3) | -0.06-0.09 | -0.06 | -50.00% (-0.03) | |
| Aug 13, 2026 | 2026 (Q2) | -0.13-0.53 | -0.06 | -783.33% (-0.47) | |
| May 07, 2026 | 2026 (Q1) | -0.13-0.16 | -0.16 | 0.00% (+0.00) | |
| Feb 12, 2026 | 2025 (Q4) | -0.07-0.19 | 0.09 | -311.11% (-0.28) | |
| Nov 06, 2025 | 2025 (Q3) | -0.10-0.06 | 0.07 | -185.71% (-0.13) | |
| Aug 07, 2025 | 2025 (Q2) | 0.03-0.06 | 0.1 | -160.00% (-0.16) | |
| May 15, 2025 | 2025 (Q1) | 0.03-0.16 | 0.14 | -214.29% (-0.30) | |
| Feb 05, 2025 | 2024 (Q4) | 0.120.09 | 0.26 | -65.38% (-0.17) | |
| Nov 14, 2024 | 2024 (Q3) | -0.010.07 | -0.09 | 177.78% (+0.16) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

